Copyright © Inderes 2011 - present. All rights reserved.

Xintela

0,26 SEK

-2,26 %

Mindre end 1K følgere

XINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-2,26 %
-40,27 %
-30,56 %
-40,82 %
-21,09 %
-17,07 %
-50,11 %
-86,40 %
-88,69 %

Xintela operates in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes on the surface of cells, which enables the identification of stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.

Læs mere
Markedsværdi
223,07 mio. SEK
Aktieomsætning
20,83 t SEK
Omsætning
4,22 mio.
EBIT %
-934,83 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
27.2
2026

Årsrapport '25

ViserAlle indholdstyper
Eksterne analyser

Xintela: Focus on study results and financing - VH Corp

• Final study results support XSTEM’s disease-modifying potential in OA • Rights issue of MSEK 72.8 announced at SEK 0.26 per share • Q&A with CEO Evy Lundgren Åkerlund on the new Targinta collaboration Xintela released its Q3 report on November 4 instead...

Xintela

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Eksterne analyser

Xintela: Awaiting final follow-up data - VH Corp

• The 24-month follow-up data to be reported by the end of Q3 • The GMP production facility is generating revenue • Adjusted for dilution, our fair value amounts to SEK 1.28 per share Xintela’s half-year report did not reveal any surprises. As announced...

Xintela
Eksterne analyser

Xintela: Taking position for the next phase - VH Corp

• Encouraging interim results with XSTEM OA • EQGen licensing deal signed regarding EQSTEM • Our fair value amounts to SEK 1.49 per share During the spring Xintela announced positive interim data from its phase I/IIa study with XSTEM in knee ostoearthritis...

Xintela
Eksterne analyser

Xintela: Licensing deal with EQGen Biomedical - VH Corp

• Q&A with EQGen’s founders CMO Willem Scheele and CEO Grant Senner • License fee of MUSD 1 and shares in EQGen worth MUSD 3 • Our model suggests a fair value of SEK 1.43 per share Xintela and EQGen have entered a licensing and development agreement ...

Xintela
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.